戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 macrophage content in plaque, and attenuated progression of disease.
2 ty, which is associated with development and progression of disease.
3 s extremely effective in reducing flares and progression of disease.
4 ADAM12 protein levels in urine increase with progression of disease.
5 ns for development of new therapies to block progression of disease.
6 action between macrophages and CX3CL1 in the progression of disease.
7  physiological control and for the onset and progression of disease.
8 ication may functionally regulate metastatic progression of disease.
9  conditions and environmental factors in the progression of disease.
10 dence for the involvement of steroids in the progression of disease.
11 ms seem to be important for the onset and/or progression of disease.
12 ence of guttae and has been used to document progression of disease.
13 resented to examine failure phenomena in the progression of disease.
14  mg daily and to consider dose escalation on progression of disease.
15 se development may prevent diabetes or delay progression of disease.
16  are believed to play important roles in the progression of disease.
17 out of the perivascular space and leading to progression of disease.
18 nses, leading to the control of infection or progression of disease.
19 ses of HD and is associated with subclinical progression of disease.
20 ds the ability to monitor both the onset and progression of disease.
21  can potentially affect various steps in the progression of disease.
22 tly implicate tau abnormalities in the onset/progression of disease.
23 at is associated with change in the onset or progression of disease.
24 n many cancers and can drive the genesis and progression of disease.
25 ed continuously beginning on day 1 and until progression of disease.
26  are implicated directly in the onset and/or progression of disease.
27 et in individual mice, we were able to track progression of disease.
28 , a highly angiogenic cytokine that supports progression of disease.
29 with an unusual joint distribution and rapid progression of disease.
30 ng cessation can reduce symptoms and prevent progression of disease.
31  to understand their role in the development/progression of disease.
32 atory agents) directed at slowing or halting progression of disease.
33 riety of organs and to observe the onset and progression of disease.
34 llowed by increased uptake of 18F-FDG during progression of disease.
35    The expression of endoglin increased with progression of disease.
36 count and HIV RNA level as predictors of the progression of disease.
37 ops into severe ataxia or paralysis with the progression of disease.
38 ot appear to either accelerate or retard the progression of disease.
39  of DNA encoding the CR1 genes prevented the progression of disease.
40 peptide accelerated rather than retarded the progression of disease.
41 nt and maintenance of the glomerulus and the progression of disease.
42  patient was when onset occurred and rate of progression of disease.
43  alive without evidence of local or systemic progression of disease.
44 ediate virus dissemination and contribute to progression of disease.
45 ls of HIV-1 RNA than those with slower or no progression of disease.
46 able to undergo surgery as a result of local progression of disease.
47 with a faster rate of CD4 T-cell decline and progression of disease.
48 te HIV-1 infection influences the subsequent progression of disease.
49 ith selegiline or alpha-tocopherol slows the progression of disease.
50  remained elevated in spinal cord throughout progression of disease.
51 utralizing virus in vitro increased with the progression of disease.
52 ed with hematopoietic malfunction during the progression of disease.
53 mis and how these adaptations can define the progression of disease.
54  pathways, contributes to the initiation and progression of disease.
55 k factors is important to help limit further progression of disease.
56 n of new functions and in the appearance and progression of disease.
57  increased TFF expression to prevent further progression of disease.
58 xtracellular protein aggregates in mediating progression of disease.
59 ts of Mendelian and somatic mutations on the progression of disease.
60 mitochondrial dysfunction and development or progression of disease.
61  mediators at specific points in time in the progression of disease.
62 cooperating mutations that are necessary for progression of disease.
63 up differences were observed in radiographic progression of disease.
64 uals, enable early diagnosis and reflect the progression of disease.
65 ions in both conditions but do not alter the progression of disease.
66  in which cytokines play a major role in the progression of disease.
67 eled deterioration of motor performance with progression of disease.
68 specific CD8(+) T cells were associated with progression of disease.
69 initiated, perpetuated, and connected in the progression of disease.
70 ly type 1 diabetic (T1D) patients during the progression of disease.
71 oncogene thought to be an early event in the progression of disease.
72 tic wall inflammation that may portend rapid progression of disease.
73 oint which mutations influence the onset and progression of disease.
74 ter surgery, 11.1% experienced recurrence or progression of disease.
75 s that break down during the development and progression of disease.
76  decrease in satellite cells correlated with progression of disease.
77 ides is critical for both the initiation and progression of disease.
78 or disease classification and to monitor the progression of diseases.
79 er of illness, or can intervention alter the progression of disease?
80 dacarbazine group (hazard ratio for death or progression of disease, 0.43; 95% CI, 0.34 to 0.56; P<0.
81 itions of cure as it applies to MS: (1) halt progression of disease, (2) reverse neurological deficit
82 ange, 8 to 45+ months), 5 patients (42%) had progression of disease 8, 12, 18, 23, and 39 months from
83 used mixed modelling techniques to model the progression of disease according to these predictors, al
84 bacteria in the intestinal flora and relapse/progression of disease after allo-HCT.
85 sed Hodgkin's lymphoma, 44 (90%) of whom had progression of disease after previous autologous transpl
86 ding patients with newly diagnosed cancer or progression of disease after remission.
87 e) OAC or other treatment methods because of progression of disease after second-line OAC, particular
88   In patients with stage III disease without progression of disease after therapy, PCI decreased the
89                                              Progression of disease also was correlated with increase
90 tion model in which we observed a more rapid progression of disease and a greater recovery rate for t
91  of endometrial cancer associated with rapid progression of disease and a poor prognosis.
92 sing questions about the determinants of the progression of disease and age at onset.
93                                              Progression of disease and bypass graft attrition result
94 n and median time from the last treatment to progression of disease and death (if applicable) was als
95                        The relative risks of progression of disease and death among the 183 women ass
96 bition as a therapeutic strategy to slow the progression of disease and delay cancer recurrence in in
97 rated greater deficits across the brain with progression of disease and development of dementia, part
98 ion of treatment was associated with greater progression of disease and did not confer immunologic or
99 n KO mice with wild-type spleen cells halted progression of disease and favored recovery.
100  processes may be beneficial for halting the progression of disease and improving quality of life in
101 ing and treatment of CMV retinitis may limit progression of disease and may prevent visual impairment
102               Treatment is needed to prevent progression of disease and minimize recurrence after liv
103 SC-EPOCH-RR group, the rates of freedom from progression of disease and overall survival were, respec
104       Several nutritional factors modify the progression of disease and prognosis after the diagnosis
105 aphy may be helpful in diagnosis, monitoring progression of disease and response to treatment.
106 er, approximately 20% of patients have early progression of disease and short OS.
107 ion; the test may be useful to follow up the progression of disease and the effect of treatment.
108 y weight, given every two weeks; the time to progression of disease and the response rate were primar
109  the oral cavity, and this may influence the progression of diseases and/or aging changes at this sit
110 had stable IFD at the end of therapy without progression of disease, and 6 (16%) patients had progres
111          Medical treatment does not slow the progression of disease, and many patients need liver tra
112 easures were control of ocular inflammation, progression of disease, and surgical success.
113 e primary determinant of clinically apparent progression of disease, and that future experimental the
114 events such as plaque rupture, to follow the progression of disease, and to select appropriate therap
115                                         With progression of disease, approximately 50% of mice acquir
116 t revascularization due to restenosis and/or progression of disease are largely unknown.
117  pathogenic mechanisms driving the onset and progression of disease are not clearly defined.
118              Nevertheless, overall onset and progression of disease are unaffected in C1q- and C3-del
119 ent followed by 2 weeks off treatment, until progression of disease as determined by the investigator
120                  The model recapitulated the progression of disease as seen during experimental infec
121 ears, namely prevention of exacerbations and progression of disease, as well as primary intervention,
122 ular interactions important in the onset and progression of disease, assessing the biologic relevance
123  these genes is linked to the initiation and progression of diseases associated with exacerbated infl
124 striatal dopamine neurons, as well as in the progression of diseases associated with this system, e.g
125              Both improved survival and less progression of disease at 5 years after elective TEVAR w
126 dentifiable, high prevalence group, allowing progression of disease at a time when therapeutic advanc
127 res that accurately reflect the pathological progression of disease at each stage.
128                        Three patients showed progression of disease at the treated levels at follow-u
129  fibre density, age-at-onset of symptoms and progression of disease burden, as measured by the Newcas
130 nts who did not undergo surgery did not have progression of disease, but approximately one quarter of
131             A total of 11/16 patients showed progression of disease by EM on follow-up biopsy.
132                      The potential for rapid progression of disease caused by encapsulated bacteria p
133 it required for filament assembly, onset and progression of disease caused by familial ALS-linked SOD
134 of various human diseases, including delayed progression of disease caused by human immunodeficiency
135               Some animals experienced rapid progression of disease characterized by loss of greater
136                              Spatio-temporal progression of disease could be described as the sum of
137 er, 14 of these 52 patients (27 percent) had progression of disease, defined as the development of at
138 cellular pathology and continuing throughout progression of disease demonstrates that tyrosine nitrat
139   Even when tumors are initially responsive, progression of disease despite continued taxane therapy
140 both processes contribute to persistence and progression of disease, despite anti-inflammatory therap
141  therapeutic regimens which prevent or delay progression of disease due to resistance.
142 ies or groups of related species and relapse/progression of disease during 2 years of follow-up time
143 sistance to paclitaxel was defined as either progression of disease during treatment, failure to achi
144 stand the role of protein aggregation in the progression of disease etiology, we performed a screen f
145 ontrol, drug resistance followed by clinical progression of disease eventually occurs in virtually al
146                                     Clinical progression of disease following initiation of HAART was
147 ocytes can contribute to the development and progression of diseases for which acute or chronic infla
148                         Infants with a rapid progression of disease had higher peak HIV-1 RNA levels
149                                The fulminant progression of disease has been largely ascribed to the
150 mediated inflammation in the acceleration or progression of disease has been proposed.
151 of miRNA, their involvement in the onset and progression of disease has generated significant interes
152  associated with a decreased risk of relapse/progression of disease (hazard ratio [HR], 0.82 per 10-f
153 edictable onset, ease of transmission, rapid progression of disease, high mortality and lack of effec
154 udy were 5.7 times more likely to experience progression of disease (HR = 5.70; 95% confidence interv
155 esence also was associated with less relapse/progression of disease (HR, 0.52; 95% CI, 0.31 to 0.87;
156 ns and did not exacerbate EAE, but i) halted progression of disease, ii) reversed neurological defici
157 dulates aggregation and delays the onset and progression of disease in a full-length model of HD, BAC
158  production of collagen-specific Abs and the progression of disease in a mouse model of rheumatoid ar
159 emented cases and remained higher throughout progression of disease in all regions examined.
160 ue injury in a developing fetus and clinical progression of disease in an asymptomatic mother found t
161 aseI gene has been shown to be important for progression of disease in both the murine and human form
162 ested the effect of CTLA4Ig treatment on the progression of disease in BXSB males.
163 f injury and inflammation increased with the progression of disease in coal miners.
164 odel for investigating NTHi pathogenesis and progression of disease in COPD.
165 f endothelial dysfunction does contribute to progression of disease in early heart failure, specific
166                 Large SDs reflected variable progression of disease in individual patients on standar
167 amin A palmitate and omega-3-rich fish, slow progression of disease in many patients.
168             This is in contrast to the rapid progression of disease in mice lacking IFN-gamma or a ke
169 l number and behavior that may relate to the progression of disease in myotubularin deficiency, and m
170  new-onset inflammation and the high risk of progression of disease in new-onset ulcerative proctitis
171 o diabetes onset can significantly delay the progression of disease in NOD mice.
172 lusively on memory CD4(+) T cells during the progression of disease in NOD mice.
173 ence of disease in the transplanted organ or progression of disease in other organs.
174 duced survival in ovarian cancer and earlier progression of disease in ovarian and endometrial cancer
175 izumab can significantly prolong the time to progression of disease in patients with metastatic renal
176 based biomarkers to monitor the activity and progression of disease in patients with ulcerative colit
177 sponse in three, stable findings in one, and progression of disease in six.
178 xamined the effect of these compounds on the progression of disease in SMN lacking exon 7 (SMNDelta7)
179  oligotyping may be useful in predicting the progression of disease in some Caucasian patients.
180  early development of symptoms and the rapid progression of disease in some vertically infected infan
181 as a significant prolongation of the time to progression of disease in the high-dose--antibody group
182 y donor with HELLP syndrome and describe the progression of disease in the liver during cold storage.
183 borderline significance, between the time to progression of disease in the low-dose--antibody group a
184 splenic neutrophils at several stages in the progression of disease in the NZB/W murine model of lupu
185 oviding a molecular explanation for the slow progression of disease in these children.
186 based intervention strategies to prevent the progression of disease in utero are also discussed.
187                                 Similarly to progression of disease in women, ovarian neoplasms sprea
188  docosahexaenoic acid (DHA) can mitigate the progression of diseases in which oxidative stress repres
189 roach ideally involves strategies to prevent progression of disease, in addition to prediction of suc
190 ion with other insults trigger the onset and progression of disease, in both familial and idiopathic
191 ession, gene regulation, development and the progression of diseases including cancer.
192                                              Progression of disease is clearly evident in the positro
193 hat induce protective immunity or retard the progression of disease is important for AIDS vaccine dev
194 is chronic airflow impairment, but the early progression of disease is not well defined or understood
195 With current therapies such as epoprostenol, progression of disease is slowed, but not halted.
196                     However, its role in the progression of disease is still being elucidated.
197 mmon reasons for not undergoing surgery were progression of disease (n = 13) and patient choice (n =
198  these findings could help explain the rapid progression of disease observed in some HIV-1-infected c
199                                   Relapse or progression of disease occurred in 54 children.
200 n nine patients (15%), and three deaths from progression of disease occurred within 30 days of withdr
201                                              Progression of diseases of the exocrine pancreas, which
202                            Two patients with progression of disease on standard three-week paclitaxel
203 muscular inoculation results in a more rapid progression of disease onset, whereas the incubation tim
204 avenously over 2 hours, every 21 days, until progression of disease or adverse effects prohibited fur
205  progression-free survival (hazard ratio for progression of disease or death from any cause, 1.05; 95
206                         The relative risk of progression of disease or death was 0.57 (95% CI, 0.43 t
207                        The relative risks of progression of disease or death were 0.57 (95 percent co
208    Study endpoints were clinical evidence of progression of disease or death.
209 those with stable disease were treated until progression of disease or intolerable toxicity.
210 risk of significant disease at diagnosis and progression of disease over time.
211                   One example of this is the progression of disease pathology found in both the neoco
212 ble disease (SD) and seven (23%) experienced progression of disease (PD).
213 ncy that enabled us to control the onset and progression of disease phenotypes by the modulation of F
214 nts with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial c
215                    However, the histological progression of disease, predictors of recurrence and dis
216 nhibitor), a papular eruption concerning for progression of disease prompted cessation of treatment.
217 matrix-adhesion pathways are involved in the progression of disease regardless of the primary insult.
218               Dysphagia may occur during the progression of disease regardless of whether the patient
219 l insults and prevent disease or inhibit the progression of diseases related to oxidative stress.
220       UDCA therapy had no effect on delaying progression of disease (relative risk, 0.95; 95% confide
221           We investigated the appearance and progression of disease-relevant signs in the B6.Htt(Q111
222 ectiveness and safety of RFA, recurrence and progression of disease remain an issue in a subset of pa
223  therapies to limit vascular leak during the progression of disease requires a more complete understa
224 d subsequent clinical events: restenosis and progression of disease requiring coronary artery bypass
225 it from treatment with an EGFR TKI; systemic progression of disease (Response Evaluation Criteria in
226                  Symptoms also increase with progression of disease severity.
227 sible by our enhanced ability to monitor the progression of disease, should make it possible to study
228 ting time and, as a result, may decrease the progression of disease so that intuitively the recurrenc
229  address both the cognitive and the biologic progression of disease state in individual subjects.
230 ase activity has long been recognized in the progression of disease states such as cancer and inflamm
231  to growth retardation in several organs and progression of disease states such as transient neonatal
232 oles in tissue remodelling and repair and in progression of diseases such as cancer, arthritis, ather
233 drive disorganization of tissues and promote progression of diseases such as cancer.
234 pregnancy outcomes, as well as its effect on progression of diseases such as HIV infection.
235 ry responses may lead to the development and progression of diseases such as hypertrophic cardiomyopa
236 ian E- and N-cadherins might function in the progression of diseases such as metastatic ovarian cance
237 lene evolution occurs concomitantly with the progression of disease symptoms in response to many viru
238 ated with a significantly longer time to the progression of disease than was treatment with cisplatin
239 A-B57 are associated with protection against progression of disease that results from infection with
240  might participate in the development and/or progression of diseases that include repeat-associated c
241 n potentially help clinicians to predict the progression of diseases, there is no method so far that
242 onally effective in slowing or reversing the progression of disease though a significant number of pa
243 y understood and often results in sufficient progression of disease to warrant evaluation for lung tr
244 nal failure (ischemic nephropathy) caused by progression of disease, usually atherosclerotic in natur
245 tment began within 2 weeks of birth, and the progression of disease was followed over time using beha
246 atal bronchopneumonia in X-CGD mice, whereas progression of disease was slower at lower doses, with d
247 xtranuclear mutant htt on the initiation and progression of disease, we generated a series of transge
248 IL-17 significantly reduces the severity and progression of disease, which is paralleled by a reducti
249 tential biomarkers that are sensitive to the progression of disease, which might enhance the diagnost
250 hs of life are at increased risk for a rapid progression of disease, which suggests that early treatm
251 y, providing new insight into the origin and progression of disease with increasing age.
252 model of melioidosis and to characterize the progression of disease with respect to clinical presenta
253  animals showed a significant slowing of the progression of disease with weight loss attenuation, enh
254 ent of the inflammasome in the initiation or progression of diseases with a high impact on public hea
255 cycline therapy, 12 of whom had demonstrated progression of disease within 12 months of it.
256  Posttreatment surrogate end points, such as progression of disease within 24 months (POD24) are prom
257 nd used intravital microscopy to monitor the progression of disease within the bone marrow at both th

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top